The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index; 92 of the 155 sources its claims cite were checked for support.
Antifungal persistence: Clinical relevance and mechanisms
Open accessAbstract
Review defining antifungal persistence as survival of a subpopulation at high drug concentrations, distinct from tolerance and resistance, and emphasizing its phenotypic, reversible nature.
Overview
CoChat Summary
TL;DR
This review defines antifungal persistence as a non-heritable, population-level phenomenon in which a small subpopulation of dormant fungal cells survives high-dose antifungals without increased MIC, distinct from resistance, tolerance, and heteroresistance. It synthesizes detection methods, mechanisms, and clinical/treatment evidence, concluding that direct clinical outcome evidence and mechanistic understanding remain limited.
Key findings
- Antifungal persistence is heterogeneous: generally <<1% of the population survives, time-kill assays show similar MDK99 to susceptible strains but substantially higher MDK99.99, and MIC does not increase; unlike resistance, it is non-heritable.
- Mechanisms include a dormant low-metabolism state (downregulated glycolysis, TCA cycle, and PPP; reduced ATP; upregulated glyoxylate cycle and gluconeogenesis), stress responses (SODs, Ahp1, ergothioneine, Hsp12, Hsp90 family), and adhesion/biofilm initiation; AmB-tolerant persisters are absent in some Candida spp. biofilms, and dormancy alone is insufficient.
- Clinical relevance: in vivo models show higher fungal burden in persistent A. fumigatus isolates after voriconazole in Galleria mellonella and higher fungal burden plus echinocandin-resistance mutation rate in N. glabratus mouse infection; long-term C. albicans oral carriers had higher persistence, and persistent candidemia isolates showed high azole tolerance.
- Treatment: persisters are recalcitrant to multiple antifungals, but cited agents including sertraline, Lavandula angustifolia essential oil, polymethacrylates, VT-1161, and gH625-M can eradicate persisters in specific models; a SOD inhibitor reduced the persister fraction by 18-fold.
Methods
- Narrative review; no primary experiments. It synthesizes definitions, distinctions from resistance/tolerance/heteroresistance, detection methods, molecular mechanisms, and in vivo/clinical observations.
- Evidence base includes cited studies in Candida spp., Cryptococcus, Aspergillus, and other fungi, using in vitro assays, animal models, and clinical observations.
- Main analysis is qualitative synthesis with figures and a treatment table; no systematic review search strategy is stated.
Limitations
- The paper states that conclusive evidence directly tying fungal persistence to clinical outcomes such as recurrent infections is still lacking, and that mechanisms remain poorly defined and multifactorial.
- The paper notes that AmB-tolerant persisters are absent in biofilms of some Candida spp., dormancy alone is insufficient, energy-metabolism studies are predominantly in biofilms and may not apply to planktonic cells, and adhesion research is limited to biofilm-associated genes, lacks specific pathways, and covers limited species.
- Evident from the text: as a narrative review, it reports no primary data or systematic search; some mechanisms are presented as likely rather than proven in persisters, as indicated by the figure legends distinguishing solid and dashed lines.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
66 Valid · 4 Not valid · 38 Not checked · 22 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“A study in the Galleria mellonella mini-host model of A. fumigatus infection found that fungal burden of the larvae infected with persistent isolates was significantly higher than non-persistent isolates after voriconazole treatment [4].”
§ Antifungal persistence: Clinical relevance and mechanisms > Clinical relevance of antifungal persistence > 1. Potential outcome of antifungal persistence
What the sources say
- Disputedcites [4] J Scott, 2023, Aspergillus fumigatus can display persistence to the fungicidal drug voriconazole, Microbiol Spectr sourceExperimental — accuracy not yet measured
The Results (Fig. 7) report higher mean fungal burden in voriconazole-treated larvae infected with persister isolates, but explicitly say the differences from nonpersister isolates were not significant. The claim's assertion of statistical significance contradicts that finding. (LLM, conf=0.94)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“N. glabratus persisters are recalcitrant to echinocandins and AmB [38].”
§ Antifungal persistence: Clinical relevance and mechanisms > Clinical relevance of antifungal persistence > 2. Treatment targeting antifungal persistence
What the sources say
- Disputedcites [38] A Arastehfar, 2023, Macrophage internalization creates a multidrug-tolerant fungal persister reservoir and facilitates the emergence of drug resistance, Nat Commun sourceExperimental — accuracy not yet measured
The Results section reports that intracellular C. glabrata persisters are highly tolerant to echinocandins, supporting that part of the claim. But the section titled “Micafungin-tolerant ICG are effectively killed by amphotericin B” reports the opposite for AmB: following micafungin with amphotericin B significantly reduced persister numbers. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Dormant cells have been observed in various cases of antifungal persistence, such as in AmB-tolerant C. albicans biofilms and in a mouse model of pulmonary cryptococcosis [3,33].”
§ Antifungal persistence: Clinical relevance and mechanisms > Mechanisms of antifungal persistence formation > 1. Dormant state promotes antifungal persistence
What the sources say
- Supportedcites [3] W Ke, 2024, Fungicide-tolerant persister formation during cryptococcal pulmonary infection, Cell Host Microbe source
The Results describe dormant C. neoformans cells in a murine inhalation model and investigate their relationship to AmB persisters. The Discussion reports that AmB persisters in the mouse lung are enriched in cells producing stationary-phase indicators. This supports the pulmonary-cryptococcosis example attributed to this source; the separate C. albicans biofilm example is not assessed here. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [33] P Li, 2015, Delicate metabolic control and coordinated stress response critically determine antifungal tolerance of Candida albicans biofilm persisters, Antimicrob Agents Chemother source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A recent study has found that reduced ATP synthesis due to limited respiration may be a key mechanism of AmB-tolerant Cryptococcus neoformans persisters formation [3].”
§ Antifungal persistence: Clinical relevance and mechanisms > Mechanisms of antifungal persistence formation > 1. Dormant state promotes antifungal persistence
What the sources say
- Supportedcites [3] W Ke, 2024, Fungicide-tolerant persister formation during cryptococcal pulmonary infection, Cell Host Microbe source
The Results section states that arsenate-induced inhibition of ATP synthesis increased survival under AmB treatment and concludes that reduced ATP synthesis due to limited respiration may be a key mechanism of AmB persistence in C. neoformans stationary-phase cells. This matches the citing sentence’s hedged claim. (LLM, conf=0.95)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, antifungal tolerance and persistence are often overlooked [17,47].”
§ Antifungal persistence: Clinical relevance and mechanisms > Clinical relevance of antifungal persistence > 1. Potential outcome of antifungal persistence
What the sources say
- Partly supportedcites [17] E Delarze, 2015, Defining the frontiers between antifungal resistance, tolerance and the concept of persistence, Drug Resist Updat sourceExperimental — accuracy not yet measured
The Abstract and §4 describe antifungal tolerance as an ignored or neglected area. Section 5 says persistence after therapy is neglected in most animal-model reports, while noting that relapses matter clinically. These passages support the broad point that both receive insufficient attention, but do not establish that they are often overlooked in clinical practice. (LLM, conf=0.85)
- Partly supportedcites [47] A Rosenberg, 2018, Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia, Nat Commun sourceExperimental — accuracy not yet measured
The Abstract (page unavailable) says antifungal tolerance is rarely quantified and that current clinical recommendations suggest ignoring it. The paper also says standard MIC testing may miss the risk of persistent infection, but it does not say that persistence itself is often overlooked in clinical practice. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
75 more claims · 38 with their cited sources checked
Create a free account to see all 130 claims and to verify the 6 references still open.
- It may state two separate claims as one. 42
- Probably not a substantial claim. 15
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Antifungal persistence: Clinical relevance and mechanisms > Clinical relevance of antifungal persistence > 2. Treatment targeting antifungal persistence
“Lavandula angustifolia essential oil, which can provoke intracellular reactive oxygen species (ROS) accumulation, has been found to successfully eradicate caspofungin-triggered Candida auris biofilm persisters [14].”
§ Antifungal persistence: Clinical relevance and mechanisms > Clinical relevance of antifungal persistence > 2. Treatment targeting antifungal persistence
“| Lavandula angustifoliaessential oil | CRYPT auris | Biofilm in vitro | Caspofungin-tolerant | [14] |”
Citations
Cites
Bacterial Persistence as a Phenotypic Switch
Balaban, N. Q., Merrin, J., Chait, R., Kowalik, L., & Leibler, S. (2004) · Science · doi:10.1126/science.1099390 · Cited by 2,952 · cited 1×
“Over time, the persistent subpopulation emerges and maintains viability, leading to longer minimum treatment durations required for 99.99% population eradication (MDK 99.99 ) [15,17,20,21] (Fig 1).”
InfluentialDonnelly, J. P., Chen, S. C., Kauffman, C. A., Steinbach, W. J., Baddley, J. W., Verweij, P. E., Clancy, C. J., Wingard, J. R., Lockhart, S. R., Groll, A. H., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1008 · Cited by 2,917
Persister cells, dormancy and infectious disease
Lewis, K. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1557 · Cited by 2,052 · cited 1×
“It has been well studied that dormant state reduces the exposure of antibiotic targets and helps bacterial cells tolerate a variety of antibiotics, a process linked to the toxin-antitoxin system [18,54].”
Lewis, K. (2010) · Annual Review of Microbiology · doi:10.1146/annurev.micro.112408.134306 · Cited by 1,858 · cited 2×
“Fungal persisters are dormant variants of wild-type cells that are tolerant to antifungal drugs, surviving high dosage of antifungals that exceed the minimal inhibitory concentration (MIC) [12,16].”
Distinguishing between resistance, tolerance and persistence to antibiotic treatment
Brauner, A., Fridman, O., Gefen, O., & Balaban, N. Q. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.34 · Cited by 1,612 · cited 2×
“For a long time, characteristic biphasic-killing curve observed in the time-kill assay and survival rate evaluated by colony-forming unit (CFU) counting were the only ways to identify and evaluate antifungal persistence in vitro [15,20].”
InfluentialRespiratory metabolism: glycolysis, the TCA cycle and mitochondrial electron transport
Fernie, A. R., Carrari, F., & Sweetlove, L. J. (2004) · Current Opinion in Plant Biology · doi:10.1016/j.pbi.2004.03.007 · Cited by 1,403 · cited 1×
“TCA cycle provides nicotinamide adenine dinucleotide as a substrate for the oxidative respiratory chain, generating a large amount of ATP [57].”
Definitions and guidelines for research on antibiotic persistence
Balaban, N. Q., Helaine, S., Lewis, K., Ackermann, M., Aldridge, B., Andersson, D. I., Brynildsen, M. P., Bumann, D., Camilli, A., Collins, J. J., et al. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0196-3 · Cited by 1,313 · cited 4×
“For a long time, characteristic biphasic-killing curve observed in the time-kill assay and survival rate evaluated by colony-forming unit (CFU) counting were the only ways to identify and evaluate antifungal persistence in vitro [15,20].”
InfluentialTREATMENT OF STAPHYLOCOCCAL INFECTIONS WITH PENICILLIN BY INTERMITTENT STERILISATION
Bigger, J. (1944) · The Lancet · doi:10.1016/s0140-6736(00)74210-3 · Cited by 1,178
Metabolite-enabled eradication of bacterial persisters by aminoglycosides
Allison, K. R., Brynildsen, M. P., & Collins, J. J. (2011) · Nature · doi:10.1038/nature10069 · Cited by 1,025 · cited 1×
“In bacteria, the addition of glycolysis intermediates can kill aminoglycoside-induced persisters [56], but such phenomenon has not been observed in fungi.”
The antifungal pipeline: a reality check
Perfect, J. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.46 · Cited by 866 · cited 1×
“Amphotericin B which belongs to polyenes class, due to its potent fungicidal activity and the rarity of resistance [35–37], has been widely studied and shown to induce antifungal persistence in Candida spp. biofilms and Trichosporon spp. Reports on echinocandin-associated persistence are primarily…”
Research works printed but not linked: 2
- A Brauner, 2016, Distinguishing between resistance, tolerance and persistence to antibiotic treatment, Nat Rev Microbiol, 14, 320, 10.1038/nrmicro.2016.34 · DOI · Paper page
- K Lewis, 2010, Persister cells, Annu Rev Microbiol, 64, 357, 10.1146/annurev.micro.112408.134306 · DOI · Paper page
Cited by
Overcoming Candida biofilm resistance: targeting persister cells with probiotic-derived metabolites
Debta, P., Sahu, B. K., Patra, S. K., Debta, F. M., Mishra, E., & Panda, S. K. (2026) · Frontiers in Antibiotics · doi:10.3389/frabi.2026.1767028 · Cited by 8
“…single-cell transcriptomics, metabolic reporters, or molecular signatures) that could be utilized as candidate biomarkers for persistence-enriched states; however, these technologies still require controlled clinical studies for further validation and optimization (Chen, 2025; Wang et al., 2025).”
Fungal Antimicrobial Resistance: Mechanisms, Drivers, and Global Clinical Burden
Baral, B. (2026) · ChemFoodChem · doi:10.1002/cfch.70026 · Cited by 2
Bacterial heteroresistance mechanisms, dynamics, and emerging diagnostic approaches
Brameyer, S. (2026) · Bioscience Reports · doi:10.1042/bsr20260035 · Cited by 1
“The conceptual parallel between bacterial heteroresistance and fungal persistence underscores that population heterogeneity under antimicrobial stress is a cross-kingdom phenomenon with shared evolutionary logic but lineage-specific molecular underpinnings [64].”
Mantilla, M. J., Tebbji, F., Vincent, A. T., Villeneuve, L. R., Chatr‐aryamontri, A., & Sellam, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.21.719916
Prevalence and phenotypic features of voriconazole persistence in Aspergillus fumigatus
Li, X., Zhou, Z., Lin, H., Guo, J., Wu, W., Goldman, G. H., Lu, L., & Zhang, Y. (2026) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2026.2679240
Metadata
- Authors
- Wang, R., Lv, J., Chen, L., Zhao, Y., & Du, H.
- Affiliations
- Second Affiliated Hospital of Soochow University (CN)
- University at Buffalo, State University of New York (US)
- Corresponding author
- Du, Hong
- Venue
- PLoS pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2025-09-11
- Volume
- 21
- Issue
- 9
- Pages
- e1013456
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC12425288
- OpenAlex
- W4414154061
- Semantic Scholar
- 352843f4aea9004e61524a11e87fa74fce25ea10
- Cited by
- 12
- References
- 80
- Citations by year
- 2026: 12
- FWCI
- 2.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Key Research and Development Project of Jiangsu Provincial Science and Technology Department (BE2023704)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Keywords
- antifungal resistance, antifungal tolerance, chronic fungal infection, recurrent fungal infection
- MeSH terms
- Clinical Relevance, Animals, Antifungal Agents, Fungi, Humans, Mycoses, Drug Resistance, Fungal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antifungal persistence: Clinical relevance and mechanisms. https://app.cochat.ai/papers/10.1371/journal.ppat.1013456
- The paper
- Wang, R., Lv, J., Chen, L., Zhao, Y., & Du, H. (2025). Antifungal persistence: Clinical relevance and mechanisms. PLoS pathogens. https://doi.org/10.1371/journal.ppat.1013456
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.